Compare CFLT & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CFLT | NUVL |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | | |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 8.0B |
| IPO Year | N/A | N/A |
| Metric | CFLT | NUVL |
|---|---|---|
| Price | $30.66 | $102.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 29 | 15 |
| Target Price | $29.13 | ★ $135.00 |
| AVG Volume (30 Days) | ★ 18.8M | 504.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.28 | N/A |
| Revenue Next Year | $16.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.64 | $55.54 |
| 52 Week High | $35.76 | $113.02 |
| Indicator | CFLT | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 69.01 | 47.74 |
| Support Level | $30.49 | $98.50 |
| Resistance Level | $30.60 | $106.57 |
| Average True Range (ATR) | 0.12 | 4.92 |
| MACD | -0.08 | -0.38 |
| Stochastic Oscillator | 98.72 | 35.93 |
Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.